Recordati Rare Diseases Canada Inc. announced today the Canadian product availability of ISTURISA® (osilodrostat) for the treatment of adult patients with Cushing's disease who have persistent or ...

Dechra announced earlier today that it has received approval from the FDA for its pergolide tablets (Zygolide; Dechra) to ...

The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism ...

The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...

The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal ...

Corcept Therapeutics (CORT) leverages Korlym’s commercial success in hypercortisolism, generating $559.3M in nine-month 2025 ...

Corcept shares crash as the FDA rejects its application for relacorilant. But is it worth buying CORT stock on the pullback?

Dechra, a global leader in veterinary specialty care, today announced the FDA approval of Zygolide ® (pergolide tablets), the ...

The FDA has issued a complete response letter for an oral selective glucocorticoid receptor antagonist under investigation for the treatment of hypertension secondary to hypercortisolism, according to ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is among the most promising growth stocks according to analysts.

The U.S. FDA dashed hopes that Corcept Therapeutics Inc. might be able to launch its selective glucocorticoid receptor antagonist in two indications in 2026, issuing a complete response letter for ...

A competitor's setback was Xeris Biopharma 's ( XERS +7.39%) gain on Hump Day. On news that a potential commercial threat to one of its three commercialized drugs had been neutralized (at least for ...